Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
valsartan, amlodipine (as amlodipine besilate)
Novartis Europharm Ltd
C09DB01
amlodipine, valsartan
Agents acting on the renin-angiotensin system
Hypertension
Treatment of essential hypertension.Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
Revision: 20
Withdrawn
2007-01-17
83 B. PACKAGE LEAFLET Medicinal product no longer authorised 84 PACKAGE LEAFLET: INFORMATION FOR THE USER IMPRIDA 5 MG/80 MG FILM-COATED TABLETS amlodipine/valsartan READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET 1. What Imprida is and what it is used for 2. What you need to know before you take Imprida 3. How to take Imprida 4. Possible side effects 5. How to store Imprida 6. Contents of the pack and other information 1. WHAT IMPRIDA IS AND WHAT IT IS USED FOR Imprida tablets contain two substances called amlodipine and valsartan. Both of these substances help to control high blood pressure. Amlodipine belongs to a group of substances called “calcium channel blockers”. Amlodipine stops calcium from moving into the blood vessel wall which stops the blood vessels from tightening. Valsartan belongs to a group of substances called “angiotensin-II receptor antagonists”. Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II. This means that both of these substances help to stop the blood vessels tightening. As a result, the blood vessels relax and blood pressure is lowered. Imprida is used to treat high blood pressure in adults whose blood pressure is not controlled enough with either amlodipine or valsartan on its own. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE IMPRIDA DO NOT TAKE IMPRIDA if you are allergic to amlodipine or to any other calcium channel blockers. This may involve itching, r Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Imprida 5 mg/80 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate) and 80 mg of valsartan. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Dark yellow, round film-coated tablet with bevelled edges, imprinted with “NVR” on one side and “NV” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of essential hypertension. Imprida is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose of Imprida is one tablet per day. Imprida 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone. Imprida can be used with or without food. Individual dose titration with the components (i.e. amlodipine and valsartan) is recommended before changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed-dose combination may be considered. For convenience, patients receiving valsartan and amlodipine from separate tablets/capsules may be switched to Imprida containing the same component doses. _ _ _Renal impairment _ There are no available clinical data in severely renally impaired patients. No dosage adjustment is required for patients with mild to moderate renal impairment. Monitoring of potassium levels and creatinine is advised in moderate renal impairment. _Hepatic impairment _ Imprida is contraindicated in patients with severe hepatic impairment (see section 4.3). Medicinal product no longer authorised 3 Caution should be exercised when administering Imprida to patients with hepatic impairment or biliary obstructive disorders (see section 4.4). In patients with mild to moderate hepatic impa Przeczytaj cały dokument